Product Overview
Structure
1 tablet contains:
active substance: phonylpiracetam - 50.00 mg or 100.00 mg;
excipients: povidone K-17, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate.
pharmachologic effect
It has a positive effect on metabolic processes, stimulates redox processes, increases the energy potential of the body due to the utilization of glucose. Increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABAA and GABAB receptors, and does not significantly affect the spontaneous bioelectric activity of the brain.
It does not affect respiration and the cardiovascular system, exhibits an unexpressed diuretic effect, and has anorexigenic activity when used as a course.
The stimulating effect is manifested in the ability to have a moderately pronounced effect, which manifests itself in relation to motor reactions, an increase in physical performance, as well as a weakening of the severity of the hypnotic effect of ethanol and hexobarbital.
The psychostimulating effect prevails in the ideational sphere.
The moderate psychostimulating effect of the drug is combined with anxiolytic activity. It has some analgesic effect, increasing the pain threshold.
The adaptogenic effect is manifested in an increase in the body's resistance to stress under conditions of excessive mental and physical stress, with fatigue, hypokinesia and immobilization, at low temperatures.
Against the background of taking the drug, an improvement in vision was noted, which manifests itself in an increase in acuity, brightness and visual fields.
Improves blood flow to the lower extremities.
Stimulates the production of antibodies in response to the introduction of an antigen, which indicates immunostimulating properties, but at the same time does not contribute to the development of immediate hypersensitivity and does not change the allergic inflammatory reaction of the skin caused by the introduction of a foreign protein.
With course use, drug dependence, tolerance, "withdrawal syndrome" do not develop.
The effect is manifested in a single dose, which is important when using the drug in extreme conditions.
Absorption: Quickly absorbed. Absolute oral bioavailability is 100%.
Distribution: Penetrates into various organs and tissues, easily passes through the blood-brain barrier. The maximum concentration in the blood (Tmax) is reached after 1 hour.
Metabolism: Not metabolized in the body.
Excretion: The half-life (T1 / 2) is 3-5 hours. It is excreted unchanged: approximately 40% - by the kidneys and 60% - with bile and sweat.
Clinical pharmacology
Children under 18 years of age (safety and efficacy of the drug have not been established).
With caution
Patients with severe organic lesions of the liver and kidneys, severe arterial hypertension, severe atherosclerosis, previous panic attacks, acute psychotic conditions proceeding with psychomotor agitation - due to the possibility of exacerbation of anxiety, panic, hallucinations and delusions, as well as patients prone to to allergic reactions to nootropic drugs of the pyrrolidone group.
Application during pregnancy and during breastfeeding
Should not be prescribed during pregnancy and lactation due to the lack of data from clinical studies.
Indications
• Neurotic conditions, manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment;
• Violations of the learning process;
• Psychoorganic syndromes, manifested by intellectual-mnestic disorders and apathetic-abulic phenomena, as well as sluggish states in schizophrenia;
• Convulsive states;
• Obesity (alimentary-constitutional genesis);
• Prevention of hypoxia, increased resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to increase mental and physical performance, correction of the daily biorhythm, inversion of the sleep-wake cycle;
• Chronic alcoholism (in order to reduce intellectual and mnestic disorders).
Application during pregnancy and lactation
Contraindications
Hypersensitivity to phonylpiracetam or any excipient in the drug.
Pregnancy and the period of breastfeeding.
Age up to 18 years (due to the lack of clinical data on the efficacy and safety of the use of phonylpiracetam in this age population).
Side effects
Interaction
The drug shows a pronounced antagonism to the cataleptic effect of neuroleptics, and also weakens the severity of the hypnotic effect of ethanol and hexobarbital.
How to take, course of administration and dosage
Inside. Take immediately after meals. The dose and duration of treatment should be determined by the physician. Doses vary depending on the characteristics of the patient's condition. The average single dose is 150 mg (100 to 250 mg); the average daily dose is 250 mg (from 200 to 300 mg). The maximum daily dose of Nanotropil® novo is 750 mg. It is recommended to take a daily dose of up to 100 mg once in the morning, and over 100 mg should be divided into 2 doses. The duration of treatment can vary from 2 weeks to 3 months, with an average of 30 days. If necessary, the course can be repeated after 1 month.
To increase efficiency - 100-200 mg once in the morning, for 2 weeks (for athletes - 3 days).
The recommended duration of drug therapy in patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg once a day (in the morning). It is not recommended to take the drug later than 15 hours.
Overdose
Treatment: symptomatic therapy.
Description
Special instructions
Release form
Tablets, 50 mg, 100 mg.
On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and printed aluminum foil varnished.
1, 2, 3, 4 or 5 blister packs with instructions for use in a cardboard box.
